Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE

Circulation

Volumn 96, Issue 7, 1997, Pages 2262-2271

  Bierhaus, Angelika ^a,f   Illmer, Thomas ^a   Kasper, Michael ^b   Luther, Thomas ^b   Quehenberger, Peter ^c   Tritschler, Hans ^c   Wahl, Peter ^d   Ziegler, Reinhard ^d   Müller, Martin ^e   Nawroth, Peter P ^e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e Asia Medica   (Germany)

^f Medizinische Klinik I   (Germany)

Author keywords

Arteriosclerosis; Atherosclerosis; Coagulation; Diabetes mellitus; Endothelium

Indexed keywords

CELL SURFACE RECEPTOR; GLYCOSYLATED PROTEIN;

ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; GLYCATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM;

EID: 0030770581     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.7.2262     Document Type: Article

References (63)

1. Brownlee M. Advanced protein glycosylation in diabetes and aging. Anna Rev Med. 1995;46:223-234.
2. Schmidt AM, Van SD, Stern DM. The dark side of glucose. Nat Med. 1995;1:1002-1004.
3. Wu JT. Advanced glycosylation end products: a new disease marker for diabetes and aging. J din Lab Anal. 1993;7:252-255.
4. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A. Immunological evidence for the presence of advanced glycation end products in atherosclerotic lesions of euglycemic rabbits. Arteriosder Tliromb Vase Biol. 1995;15:571-582.
5. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol. 1995;147:654-667.
6. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL1 induced by glucose-modified proteins: role in normal tissue remodelling. Science. 1988;240:1546-1548.
7. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induced transendothelial monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease and diabetes and aging. Proc NatlAcad Sei USA. 1990;S7:9010-9014.
8. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995; 1:447-456.
9. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern DM. Advanced glycation endproducts interacting with their endothclfal receptor induce expression of vascular cell adhesion molecule-l (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest. 1995;96:1395-1403.
10. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 19S9;170:1387-1407.
11. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med. 1991;174:515-524.
12. Schmidt A-M, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y-C, Tsang T, Stern D. Isolation and characterisation of binding proteins for advanced glycation end products from lung tissue which are present on the endothelial surface. J Biol Clicm. 1992;267:1498714997.
13. Keeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chcm. 1992;267:14998-15004.
14. Schmidt AM, Mora R, Cao R, Yan SD, Brett J, Ramakrishnan R, Tsang TC, Simionescu M, Stern D. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide.7Biol Chcm. 1994;269:9S82-9888.
15. Li Y-M, Tan A-X, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycationmodified proteins to a conserved motif. Nat Med. 1995;1:1057-1061.
16. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu F-T, Cerami A. Identification of galectin-3 as a high affinity binding protein for advanced glycation end products (AGEs): a new member of the AGE-receptor complex. Mol Mcd. 1996;l:634-646.
17. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest. 1993;91:2155-2168.
18. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Keeper M, Przysiecki C, Shaw A, Migheli A, Stern D. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993;143: 1699-1712.
19. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, Allenberg J, Otto G, Roth H, Bierhaus A, Ziegler R, Schmidt AM, Waldherr R, Wahl P, Stern DM, Kawroth PP. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol. 1995;146:688-694.
20. Greten J, Zhang Y, Wiesel R, Ritz E, Ziegler R, Wahl P, Kawroth PP. Expression of receptors for advanced glycation end products in uremia. Ncphrol Dial Transplant. 1996;1 1:786-790.
21. Cybulsky MI, Collins T, Kume K, Gimbrone MA Jr. Localized expression of a mononuclear leukocyte adhesion molecule by vascular endothelium during atherogenesis. In: van Furth R, ed. Mononuclear Phagocytes. Amsterdam, Netherlands: Kluwer Academic Publishers; 1992:155-160.
22. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, Stern D. The receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Nail Acad Sei USA. 1994;91:8807-8811.
23. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern DM, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 1996;97:238-243.
24. Kemerson Y. Tissue factor and hemostasis. Blood. 1988:71:1-8.
25. Bach R. Initiation of coagulation by tissue factor. CRC Crit Rev Biochcm. 1988;23:339-368.
26. Nawroth PP, Stern DM, Kisiel W, Bach R. Cellular requirements for tissue factor generation by bovine aortic endothelial cells in culture. Tliromb Res. 19S5;40:677-691.
27. Morrissey JH, Drake TA. Procoagulant response of the endothelium and monocytes. In: Schlag G, RedI H, eds. Pathophysiology of Shock, Sepsis and Organ Failure. Berlin, Germany: Springer Verlag; 1993:564-574
28. Contrino J, Hair G, Kreutzer D, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2: 209-215.
29. Bierhaus A, Zhang Y, Deng Y, Mackman N, Ouehenberger P, Haase M, Luther T, Müller M, Bohrer H, Greten J, Martin E, Baeuerle PA, Waldherr R, Kisiel W, Ziegler R, Stern DM, Nawroth PP. Mechanism of the TNFa mediated induction of endothelial tissue factor. J Biol Chem. 1995;270:26419-26432.
30. Zhang Y, Deng Y, Wendt T, Liliensiek B, Bierhaus A, Chen B, She M, Männel D, Bachmann S, Waldherr R, Ziegler R, Stern D, Nawroth PP. Intravenous gene transfer with antisense tissue factor reduces the tumor necrosis factor induced tissue factor expression and fibrin formation on the endothelium of mouse Meth-Asarcoma. J Clin Invest. 1996;97:2213-2224.
31. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubmann MB. Tissue factor is rapidly induced in arterial smooth muscle cells after balloon injury. / din Invest. 1993;91:2253-2259.
32. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sei USA. 19S9;86:2839-2843.
33. Bromberg ME, Königsberg WH, Madison JE, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sei USA. 1995;92: 8205-8209.
34. Zhang YM, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern D, Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. / din Invest. 1994;94:1320-1327.
35. Drake TA, Zheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol. 1993;142:1458-1470.
36. Zhang Y, Bachmann S, Hemmer C, Van Lunzen J, Von Stemm A, Kern P, Dietrich M, Ziegler R, Waldherr R, Nawroth PP. Vascular origin of Kaposi's sarcoma: expression of leukocyte adhesion molecule-l, thrombomodulin and tissue factor. Am J Patliol. 1994; 144:51-59.
37. Wendt T, Zhang Y, Bierhaus A, Kriegsmann J, Deng Y, Waldherr R, Teske T, Luther T, Fünfstück R, Nawroth PP, Stein G. Tissue factor expression in an animal model of hydronephrosis. Nephrol Dial Transplant. 1995;10:1820-1828.
38. Moll T, CzyzM, Holzmüller H, Hofer-Warbinek R, Wagner E, .Winkler H, Bach FH, Hofer E. Regulation of the tissue factor promotor in endothelial cells. / Biol Chem. 1995;270:3849-3857.
39. Mackman N. Regulation of the tissue factor gene. FASEBJ. 1995; 9:883-889.
40. Parry GCN, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Tliromb Vase Biol. 1995;15:612-621.
41. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/ binding proteins. J Biol Chem. 1994;269:9889-9S97.
42. Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aok N. Determination of plasma tissue factor antigen and its clinical significance in diabetes. Dr J Hacmatol. 1994;87:343-347.
43. Wagner R. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994;372:333-335.
44. Marcus-Sekura C. Techniques for using antisense oligodeoxyribonucleotides to study gene expression. Anal Biochem. 1988;172: 289-295.
45. Eder PS, De Vine RJ, Dagle JM, Walder JA. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. Antisense Res Dev. 1991;1:141-151.
46. Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothclial and smooth muscle cells. J Dial Chem. 1994; 269:14149-14152.
47. Mackman N, Fowler BJ, Edgington TS, Morrissey JH. Functional analysis of the human tissue factor promoter and induction by serum. Pwc NailAcad Sei USA. 1990;87:2254-2258.
48. Scarpati EM, Wen D, Broze G, Miletich JP, Flandcrmayer RR, Siegel NR, Sadlcr E. Human tissue factor: cDNA-sequence and chromosome localisation of the gene. Biochemistry. 1987;26: 5234-5238.
49. Pötgens AJG, Lubsen N, van Alten G, Schoenmakers JGG, Ruiter DJ, de Waal RMW. Measurement of tissue factor messenger RNA levels in human endothelial cells by a quantitative RT-PCR assay. Tliromb Haemost. 1994;71:20S-213.
50. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. / Exp Med. 19S6;163:740-745.
51. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical cord veins: identification by morphological and immunological criteria. J Clin Invest. 1973;52: 2745-2753.
52. Greenberg NE, Ziff ME. Stimulation of 3T3 cells induce transcription of c-fos protooncogene. Nature. 1984;311:433-438.
53. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Müller M, Mackman N, Ziegler R, Nawroth PP. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-xB. Tliromb Haemost. 1997;77:772-782.
54. Schmidt AM, Hori O, Brett J, Van SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Tliromb. 1994;14: 1521-1528.
55. Burgess XL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LH, Cohen AM, Herrëra CJ, Hu SSF, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL. The antiproliferative activity of c-myb and c-inyc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acatl Sei USA. 1995;92:4051-4055.
56. Bennett CF, Condon TP, Grimm S, Chan H, Chiang M-Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. / Immunol. 1994;152:3530-3540.
57. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-nyc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol. 19S8;8:963-973.
58. Ferez JR, Li Y, Stein CA, Majumder S, van Orschot A, Narayanan R. Sequence-independent induction of SP-1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc NatlAcad Sei USA. 1994;91:5957-5961.
59. Read MA, Whitley MZ, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Etp Med. 1994;179:503-512.
60. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents: is the bullet really magic? Science. 1993;261:1004-1012.
61. Gao W-Y, Man F-S, Storm C, Egan W, Cheng Y-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerase and RNAse H: implications for antisense technology. Mol Ptiannacol. 1992;41:223-229.
62. Boiziau C,-Moreau S, Toulme JJ. A phosphorothioate oligonucleotide blocks reverse transcription via an antisense mechanism. FEES Lett. 1994;340:236-240.
63. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt A-M, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E, Waldherr R, Stern DM, Nawroth PP. Expression of receptors for advanced glycosylated end products in renal disease. Nephrol Dial Transplant. 1995;10: 1662-1667.